The Synergism Or Long Duration (SOLD) Study

NCT00593697 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2168

Enrollment

OTHER

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: trastuzumab (9 weeks) + docetaxel
DRUG: trastuzumab (9 weeks) + docetaxel + CEF + trastuzumab (up to 51 weeks)

Sponsor

Finnish Breast Cancer Group